V.D. de Jager

Faculteit Medische Wetenschappen/UMCG

Telefoon:

E-mail:

v.d.de.jager umcg.nl

ORCID Research Portal

Publicaties

Corrigendum to "Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands" [Eur J Cancer 205 (2024)114125]

de Jager, V. D., Cajiao Garcia, B. N., Kuijpers, C. C. H. J., de Bock, G. H., Maas, W. J., Timens, W., van Kempen, L. C., van der Wekken, A. J., Schuuring, E. & Willems, S. M., 26-mrt.-2026, In: European Journal of Cancer. 237, 116597.

Onderzoeksoutput

Detection of actionable mutations in circulating tumor DNA for non-small cell lung cancer patients

van der Leest, P., Rozendal, P., Rifaela, N., van der Wekken, A. J., Kievit, H., de Jager, V. D., Sidorenkov, G., van Kempen, L. C., Hiltermann, T. J. N. & Schuuring, E., dec.-2025, In: Communications medicine. 5, 10 blz., 204.

Onderzoeksoutput › › peer review

Fostering the implementation of liquid biopsy in clinical practice: meeting report 2024 of the European Liquid Biopsy Society (ELBS)

Pantel, K., Alix-Panabières, C., Hofman, P., Stoecklein, N. H., Lu, Y. J., Lianidou, E., Giacomini, P., Koch, C., de Jager, V., Deans, Z. C., Fairley, J., Patton, S. J., Toledo, R. A., Schuuring, E., Heitzer, E., Hendrix, A., Ricklefs, F. L., Thakur, B. K., von Bubnoff, N. & Pierga, J. Y., Gebhardt, C., Andersen, C. L., Fijneman, R., Malats, N., Hallermayr, A., Chelala, C., Joosse, S. A. & Ciliberto, G., 23-mei-2025, In: Journal of Experimental and Clinical Cancer Research. 44, 9 blz., 156.

Onderzoeksoutput › › peer review

Large language model-based approach for low-cost, rapid and accurate automated extraction of predictive biomarker testing results from Dutch pathology reports

de Jager, V. D., van der Ree, M., Garcia, B. C., Kuijpers, C., van der Wekken, A. J., van Kempen, L. C., Schuuring, E. & Willems, S. M., 29-nov.-2025, (E-pub ahead of print) In: Virchows Archiv : an International Journal of Pathology. 9 blz.

Onderzoeksoutput › › peer review

Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop

ELBS ctDNA Workshop Group, de Jager, V. D., Giacomini, P., Fairley, J. A., Toledo, R. A., Patton, S. J., Joosse, S. A., Koch, C., Deans, Z. C., Pantel, K., Heitzer, E. & Schuuring, E., apr.-2025, In: EBioMedicine. 114, 15 blz., 105636.

Onderzoeksoutput: Review article › peer review

112P Reporting of molecular test results from cell-free DNA analyses: Expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA workshop

de Jager, V. D., Giacomini, P., Fairley, J. A., Toledo, R. D. A., Patton, S., Joosse, S., Koch, C., Deans, S., Heitzer, E. & Schuuring, E., 1-sep.-2024, In: Annals of Oncology. 35, blz. S259

Onderzoeksoutput ›

Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries

de Jager, V. D., Timens, W., Bayle, A., Botling, J., Brcic, L., Büttner, R., Fernandes, M. G. O., Havel, L., Hochmair, M. J., Hofman, P., Janssens, A., Johansson, M., van Kempen, L., Kern, I., Lopez-Rios, F., Lüchtenborg, M., Machado, J. C., Mohorcic, K., Paz-Ares, L. & Popat, S., Ryška, A., Taniere, P., Wolf, J., Schuuring, E. & van der Wekken, A. J., mrt.-2024, In: The Lancet Regional Health - Europe. 38, 16 blz., 100838.

Onderzoeksoutput: Review article › peer review

Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer

de Jager, V. D., Timens, W., Bayle, A., Botling, J., Brcic, L., Büttner, R., Fernandes, M. G. O., Havel, L., Hochmair, M., Hofman, P., Janssens, A., van Kempen, L., Kern, I., Machado, J. C., Mohorčič, K., Popat, S., Ryška, A., Wolf, J., Schuuring, E. & van der Wekken, A. J., mrt.-2024, In: The Lancet Regional Health - Europe. 38, 9 blz., 100839.

Onderzoeksoutput: Review article › peer review

Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy

de Jager, V. D., Plomp, P., Paats, M. S., van Helvert, S., Elst, A. T., van den Berg, A., Dubbink, H. J., van Geffen, W. H., Zhang, L., Hendriks, L. E. L., Hiltermann, T. J. N., Hiddinga, B. I., Hijmering-Kappelle, L. B. M., Jalving, M., Kluiver, J., Koopman, B., van Kruchten, M., van der Logt, E. M. J., Piet, B. & van Putten, J., Reitsma, B. H., Rutgers, S. R., de Vries, M., Stigt, J. A., Groves, M. R., Timens, W., Willems, S. M., van Kempen, L. C., Schuuring, E. & van der Wekken, A. J., nov.-2024, In: ESMO Open. 9, 11, 12 blz., 103966.

Onderzoeksoutput › › peer review

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

de Jager, V. D., Stigt, J. A., Niemantsverdriet, M., Ter Elst, A. & van der Wekken, A. J., 22-mei-2024, In: NPJ precision oncology. 8, 1, 4 blz., 113.

Onderzoeksoutput › › peer review